Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 1.15 is in line with its 1-year average of 1.26, near the low end of its 1-year range (1.15–1.39).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.15.
QUICK RATIO (ACID-TEST)
1.15
QUICK RATIO (ACID-TEST) AVG TTM
N/A
QUICK RATIO (ACID-TEST) AVG 3Y
N/A
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 870 covered companies
CURRENT VS SECTOR MEDIAN
-65.79%
vs the sector median at left
Starling Oncology, Inc.
Market Cap
$657.89M
Quick Ratio (Acid-Test)
1.15
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$656.59M
Quick Ratio (Acid-Test)
8.03
TTM Avg
12.16
3Y Avg
13.50
5Y Avg
14.42
Market Cap
$660.29M
Quick Ratio (Acid-Test)
5.53
TTM Avg
8.02
3Y Avg
10.47
5Y Avg
14.43
Market Cap
$666.95M
Quick Ratio (Acid-Test)
10.97
TTM Avg
8.63
3Y Avg
10.75
5Y Avg
10.66
Market Cap
$673.41M
Quick Ratio (Acid-Test)
4.79
TTM Avg
3.80
3Y Avg
3.38
5Y Avg
3.21
Market Cap
$638.20M
Quick Ratio (Acid-Test)
16.82
TTM Avg
9.46
3Y Avg
14.12
5Y Avg
14.05
Market Cap
$681.02M
Quick Ratio (Acid-Test)
2.22
TTM Avg
3.07
3Y Avg
3.97
5Y Avg
5.01
Market Cap
$681.27M
Quick Ratio (Acid-Test)
13.82
TTM Avg
5.67
3Y Avg
7.51
5Y Avg
7.66
Market Cap
$634.30M
Quick Ratio (Acid-Test)
5.12
TTM Avg
4.05
3Y Avg
4.17
5Y Avg
7.50
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Starling Oncology, Inc. (STLN) | $657.89M | 1.15 | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | 8.03 | 12.16 | 13.50 | 14.42 |
| Annexon, Inc. (ANNX)vs › | $660.29M | 5.53 | 8.02 | 10.47 | 14.43 |
| Helus Pharma Inc. (HELP)vs › | $666.95M | 10.97 | 8.63 | 10.75 | 10.66 |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 4.79 | 3.80 | 3.38 | 3.21 |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | 16.82 | 9.46 | 14.12 | 14.05 |
| Verastem, Inc. (VSTM)vs › | $681.02M | 2.22 | 3.07 | 3.97 | 5.01 |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | 13.82 | 5.67 | 7.51 | 7.66 |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 5.12 | 4.05 | 4.17 | 7.50 |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | 3.05 | 5.21 | 6.01 | 5.25 |
Quick Ratio
1.15
Excludes inventory
Current Ratio
1.36
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 1.15 |
| 2026-03-31 | 1.17 |
| 2025-12-31 | 1.35 |
| 2025-09-30 | 1.39 |
